附件 99.1

Citius PharmPharmticals Execute达成最终协议，将全资子公司与TenX Keane收购合并，成立上市公司Citius Oncology，Inc.

Citius 制药公司将获得Citius Oncology，Inc.6.75亿美元的股权，并在交易后保留公开上市的Citius Oncology，Inc.约90%的多数控制权

交易 预计将于2024年上半年完成

美国新泽西州克兰福德和纽约2023年10月24日电花旗制药公司(以下简称“花旗制药”或“公司”) (纳斯达克股票代码：CTXR)，一家开发和商业化一流危重护理产品的生物制药公司与一家上市特殊用途收购公司TenX Keane(“TenX”)(纳斯达克：Tenku)今天宣布，他们已于2023年10月23日签订了一项最终协议。对于拟议中的TenX和Citius Pharma的全资肿瘤学子公司 的合并，该子公司将继续作为一家在纳斯达克交易所上市的上市公司。新合并的上市公司将命名为Citius Oncology， Inc.(“Citius Oncology”)。根据合并协议的条款，完成交易后，Citius Pharma将以每股10美元的价格获得6,750万股Citius Oncology的股份，并保留约90%的多数股权。这笔交易已获得两家公司董事会的批准，预计将于2024年上半年完成。

Citius 肿瘤学概述

Citius肿瘤学将作为开发和商业化新型靶向肿瘤学疗法的平台。该公司正在寻求LYMPHIR的美国食品和药物管理局(FDA)的批准，作为治疗持续性或复发性皮肤T细胞淋巴瘤(CTCL)的孤儿适应症。CTCL是一种罕见的非霍奇金淋巴瘤。管理层估计，LYMPHIR的初始市场目前超过4亿美元，正在增长，现有疗法无法提供足够的服务。如果获得批准，LYMPHIR将成为唯一一种针对CTCL疗法的IL-2受体靶向疗法，为循环接受多种治疗的患者提供了一种新的选择。强大的知识产权保护 涵盖孤儿药物指定、复杂的技术、商业秘密和正在申请的免疫肿瘤学专利，作为检查点抑制剂的联合疗法 将进一步支持Citius Oncology的竞争地位。

正在为2024年初重新提交生物制品许可证申请(BLA)进行准备工作。如果获得批准，LYMPHIR最早可能在2024年下半年用于治疗CTCL。在更大的市场中创造价值的其他机会包括外周T细胞淋巴瘤的潜在适应症或作为CAR-T和PD-1抑制剂的联合疗法，在美国以外的市场 目前正在进行两项由研究人员发起的试验，以探索LYMPHIR作为免疫肿瘤联合疗法的潜力。

这笔交易预计将为Citius Oncology提供更好的公开股票市场准入，从而促进LYMPHIR的商业化 ，并使公司能够更充分地探索更多创造价值的机会。

Citius Pharma和TENX评论

我们 相信这笔交易将使我们能够释放LYMPHIR的价值，并使Citius Pharma稳固地推进我们多样化的 渠道。这笔交易将使Citius Oncology能够进入更广泛的资本市场，如果获得批准，将更好地支持LYMPHIR的成功商业化，并探索更多潜在的肿瘤靶向疗法。我们的多数股权地位和共享服务协议确保Citius Pharma管理团队将继续全力参与Citius Oncology的开发和商业化工作。正如之前宣布的那样，该公司正在制定向其股东分配Citius Oncology部分股份的计划。在Citius Pharma，我们打算专注于完成Mino-Lok试验，并继续 评估我们的Halo-Lido计划的下一步行动，“Citius Pharma董事长兼首席执行官Leonard Mazur说。

TenX董事长兼首席执行官袁晓峰表示：“我们非常高兴地宣布与Citius Oncology拟议中的合并。”在与外部顾问一起进行了探索和评估众多潜在业务合并目标的全面流程后，我们的董事会和管理团队相信，与Citius Oncology的交易代表着为我们的股东创造实质性价值的最佳机会。如果完成这一业务合并，TenX投资者将拥有该公司的股权，该公司 专注于开发和商业化LYMPHIR，以改善CTCL患者的生活，并 与具有更大潜在市场的其他药物作为免疫肿瘤疗法的组合带来额外的潜在好处。我们很高兴能在Citius Oncology发展的转折点支持Citius Oncology，并为Citius迅速实现其发展里程碑提供一条途径。“

拟议的合并协议

根据拟议的协议，TenX将通过合并收购Citius Pharma的全资子公司，新合并的上市公司将命名为Citius Oncology，Inc.。在交易中，Citius Pharma的全资子公司的所有股份将 转换为获得Citius Oncology普通股的权利。因此，完成交易后，Citius Pharma将获得6,750万股Citius Oncology的普通股，按每股10美元的隐含价值计算，在扣除费用和费用之前，Citius Pharma将获得Citius Oncology 6.75亿美元的股权。作为交易的一部分，Citius Pharma将向Citius Oncology捐赠1,000万美元现金。Citius Oncology将承担额外的 1275万个现有选项。

交易完成时，TenX信托账户中的任何剩余现金以及Citius Pharma提供的现金都将捐给Citius肿瘤学，以支持持续运营和计划中的商业化努力。对来自TenX信托账户的可用现金和保留的交易收益的引用取决于TenX的公众股东的任何赎回以及支付交易费用和 费用。

完成交易后，Citius Oncology将根据与Citius Pharma达成的共享服务协议运营，Citius Pharma将按季度向Citius Pharma支付费用，由首席执行官Leonard Mazur、首席财务官Jaime Bartushak和首席医疗官Myron Chuuczman博士领导的Citius Pharma团队的几名关键成员提供服务。迈伦·霍卢比亚克将担任Citius Oncology董事会的执行副主席。

这笔交易已得到Citius Pharma和TenX两家董事会的一致批准，但还需得到TenX股东的批准和其他惯常的成交条件。Citius Pharma作为Citius Oncology普通股的唯一持有人，已经批准了这笔交易。 拟议的业务合并预计将于2024年上半年完成。

交易条款的更详细描述和业务合并协议的副本将包括在花旗制药和TenX各自向美国证券交易委员会(“美国证券交易委员会”)提交的最新8-K表格中 。 关于交易，TenX打算向 美国证券交易委员会提交注册声明(其中将包含委托书/招股说明书)。

本新闻稿不应构成出售或邀请购买本文所述任何证券的要约， 在任何州或司法管辖区的任何州或司法管辖区内，在根据任何此类州或司法管辖区的证券法进行登记或取得资格之前，不得出售此类证券 。

建议Citius Pharma和TENX股东及其他感兴趣的人士阅读注册说明书和初步委托书/招股说明书及其任何修正案，以及与业务合并有关的最终委托书/招股说明书，因为这些文件将包含有关Citius Pharma、TENX、Citius Oncology和拟议合并的重要信息。

邮箱：ir@citiuspharma.com

Citius 制药媒体联系人：

搅动通信

格雷格·萨尔斯堡

邮箱：greg@stir-iciations.com

TenX 联系人

泰勒 张

邮箱：Target@TenXkeane.com

About Citius Oncology, Inc.

Citius Oncology is a late-stage pharmaceutical company focused on developing and commercializing targeted oncology therapies. Its strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and leveraging competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies.

Citius Oncology’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. Management believes the market for LYMPHIR for CTCL, estimated to exceed $400 million, is attractive, growing and underserved by existing treatments. On July 28, 2023, the FDA issued a complete response letter (CRL) in response to the LYMPHIR BLA. The FDA is requiring enhanced product testing and additional controls agreed to with the FDA during the market application review. There were no concerns relating to the safety and efficacy of the clinical data package submitted with the BLA, or the proposed prescribing information. In September 2023, Citius Pharma announced that the FDA has agreed with the plans to address the requirements outlined in the CRL. This guidance has clarified the path forward in completing the necessary activities to support the resubmission of the BLA for LYMPHIR. The BLA resubmission is anticipated in early 2024.

Citius Oncology was founded in August 2021 as Citius Acquisition Corp., a Delaware corporation and wholly owned subsidiary of Citius Pharma and began operations in April 2022. The corporate name was changed to Citius Oncology, Inc. in May 2023.

About Citius Pharmaceuticals, Inc.

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company’s diversified pipeline includes two late-stage product candidates. Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, is enrolling patients in a Phase 3 Pivotal superiority trial and was granted Fast Track designation by the FDA. Citius Pharma is preparing to resubmit the Biologics License Application for LYMPHIR, a novel IL-2R immunotherapy for an initial indication in CTCL, in early 2024. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023, Citius Pharma completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

About TenX Keane Acquisition

TenX Keane Acquisition is a blank check company, also commonly referred to as a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. TenX is led by Xiaofeng Yuan, Chairman and Chief Executive Officer, and Taylor Zhang, Chief Financial Officer, who are growth-oriented executives with a long track record of value creation across industries.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the products offered by Citius Pharma and Citius Oncology and the markets in which each operates, and Citius Pharma and Citius Oncology’s projected future results. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as “believe,” “anticipate,” “estimate,” “expect,” “plan,” “would,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Citius Pharma’s common stock; the risk that the transaction may not be completed by TenX’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by TenX; the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the business combination agreement by the stockholders of TenX; the satisfaction of the minimum trust account amount following redemptions by TenX’s public stockholders; the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; the effect of the announcement or pendency of the transaction on Citius Pharma’s business relationships, performance, and business generally; risks that the proposed business combination disrupts current plans or operations of Citius Pharma; the outcome of any legal proceedings that may be instituted against Citius Pharma or TenX related to the business combination agreement or the proposed business combination; the ability to maintain the listing of TenX’s securities (which would be Citius Oncology securities) on Nasdaq after the closing of the transaction; after the closing of the transaction, the price of Citius Oncology’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Citius Oncology will operate, variations in performance across competitors, changes in laws and regulations affecting Citius Oncology’s business and changes in its capital structure; the ability to implement business plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional opportunities provided by the business combination; the cost and timing of the resubmission of the BLA for LYMPHIR; the FDA may not approve our BLA for LYMPHIR; our need for substantial additional funds; the estimated markets for our product candidates and the acceptance thereof by any market; our ability to commercialize our products if approved by the FDA; our dependence on third-party suppliers; the ability of our product candidates to impact the quality of life of our target patient populations; our ability to successfully undertake and complete clinical and non-clinical trials and the results from those trials for our product candidates; risks relating to the results of research and development activities, including those from existing and new pipeline assets; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth strategy; patent and intellectual property matters; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19 and global geopolitical events, such as the war in Ukraine and the Middle East. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings which are available on the SEC’s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2022, filed with the SEC on December 22, 2022 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Citius Pharmaceuticals Investor Contact:

Ilanit Allen

ir@citiuspharma.com

Citius Pharmaceuticals Media Contact:

STiR-communications

Greg Salsburg

Greg@STiR-communications.com

TenX Contact

Taylor Zhang

target@TenXkeane.com